CN108938667B - 一种用于药物筛选的阿尔兹海默症模型的构建方法 - Google Patents
一种用于药物筛选的阿尔兹海默症模型的构建方法 Download PDFInfo
- Publication number
- CN108938667B CN108938667B CN201811135578.2A CN201811135578A CN108938667B CN 108938667 B CN108938667 B CN 108938667B CN 201811135578 A CN201811135578 A CN 201811135578A CN 108938667 B CN108938667 B CN 108938667B
- Authority
- CN
- China
- Prior art keywords
- zebra fish
- test
- alzheimer
- disease
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000007877 drug screening Methods 0.000 title claims abstract description 16
- 241000252212 Danio rerio Species 0.000 claims abstract description 175
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241001465754 Metazoa Species 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000006698 induction Effects 0.000 claims abstract description 7
- 238000012216 screening Methods 0.000 claims abstract description 7
- 238000012360 testing method Methods 0.000 claims description 126
- 230000009182 swimming Effects 0.000 claims description 42
- 230000006399 behavior Effects 0.000 claims description 37
- 241000251468 Actinopterygii Species 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 230000015654 memory Effects 0.000 claims description 12
- 210000004556 brain Anatomy 0.000 claims description 11
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims description 9
- 244000062645 predators Species 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- 238000007619 statistical method Methods 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000010276 construction Methods 0.000 claims description 3
- 230000037023 motor activity Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 241001098657 Pterois Species 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000006978 adaptation Effects 0.000 claims 1
- 230000008897 memory decline Effects 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 31
- 238000000465 moulding Methods 0.000 abstract description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium chloride Substances Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 230000003950 pathogenic mechanism Effects 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 20
- 239000003642 reactive oxygen metabolite Substances 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 18
- 210000005013 brain tissue Anatomy 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 11
- ZRJBHWIHUMBLCN-SEQYCRGISA-N huperzine a Chemical compound N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 11
- 239000011592 zinc chloride Substances 0.000 description 10
- 238000005192 partition Methods 0.000 description 9
- 238000012545 processing Methods 0.000 description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 8
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 7
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000006403 short-term memory Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000011701 zinc Substances 0.000 description 5
- 102000012440 Acetylcholinesterase Human genes 0.000 description 4
- 108010022752 Acetylcholinesterase Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 229940022698 acetylcholinesterase Drugs 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000012301 transgenic model Methods 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000009189 diving Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108010008359 protein kinase C lambda Proteins 0.000 description 3
- 238000001223 reverse osmosis Methods 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 241000283070 Equus zebra Species 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 108091077621 MAPRE family Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- QNDQILQPPKQROV-UHFFFAOYSA-N dizinc Chemical compound [Zn]=[Zn] QNDQILQPPKQROV-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011173 large scale experimental method Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000007607 synaptic alteration Effects 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 108700024526 zebrafish sox32 Proteins 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811135578.2A CN108938667B (zh) | 2018-09-28 | 2018-09-28 | 一种用于药物筛选的阿尔兹海默症模型的构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811135578.2A CN108938667B (zh) | 2018-09-28 | 2018-09-28 | 一种用于药物筛选的阿尔兹海默症模型的构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108938667A CN108938667A (zh) | 2018-12-07 |
CN108938667B true CN108938667B (zh) | 2020-10-30 |
Family
ID=64471146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811135578.2A Active CN108938667B (zh) | 2018-09-28 | 2018-09-28 | 一种用于药物筛选的阿尔兹海默症模型的构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108938667B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110506708B (zh) * | 2019-09-24 | 2021-12-17 | 深圳大学 | 一种阿尔茨海默症小鼠模型及评价方法 |
CN111388684A (zh) * | 2020-03-26 | 2020-07-10 | 杭州医学院 | 一种利用转基因斑马鱼评价药物抗阿尔茨海默症药效的方法 |
CN112870384A (zh) * | 2021-02-04 | 2021-06-01 | 山东省科学院生物研究所 | 一种基于行为和生化指标的抗阿尔兹海默症药物的筛选方法及用该方法筛选的药物 |
-
2018
- 2018-09-28 CN CN201811135578.2A patent/CN108938667B/zh active Active
Non-Patent Citations (2)
Title |
---|
斑马鱼阿尔茨海默病动物模型的建立;浦韵竹;《西南大学2013年硕士毕业论文》;20131231;第7-23页 * |
锌与阿尔茨海默病;王琪等;《中国实用医药》;20120131;第249-251页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108938667A (zh) | 2018-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108938667B (zh) | 一种用于药物筛选的阿尔兹海默症模型的构建方法 | |
Juraska et al. | Plasticity in adult rat visual cortex: An examination of several cell populations after differential rearing | |
Stewart et al. | Modeling anxiety using adult zebrafish: a conceptual review | |
Dadda et al. | Early differences in epithalamic left–right asymmetry influence lateralization and personality of adult zebrafish | |
Grubbs et al. | A salt-induced kinase is required for the metabolic regulation of sleep | |
Einarson et al. | Variations in the basophilia of nerve cells associated with increased cell activity and functional stress | |
Lok et al. | Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer's disease | |
Nishida et al. | Prion protein is necessary for latent learning and long-term memory retention | |
Sharma et al. | Lower vertebrate and invertebrate models of Alzheimer's disease–A review | |
CN104479027B (zh) | 一种防治老年痴呆的药物 | |
CN112870384A (zh) | 一种基于行为和生化指标的抗阿尔兹海默症药物的筛选方法及用该方法筛选的药物 | |
CN102265806A (zh) | 抗阿尔茨海默症转基因果蝇模型及其在药物筛选中的应用 | |
Tamada et al. | Genetic dissection identifies Necdin as a driver gene in a mouse model of paternal 15q duplications | |
Abdulateef et al. | The effect of the electric shock on embryonic development and neurophysiological traits in the chick’s embryo | |
Hansen et al. | Influence of season and environment on adult neurogenesis in the central olfactory pathway of the shore crab, Carcinus maenas | |
CN113440600A (zh) | 枸杞糖肽用于制备缓解焦虑情绪的药物的用途 | |
Fuss et al. | It's in the eye of the beholder: visual lateralisation in response to the social environment in poeciliids | |
Ross et al. | Alligator mississippiensis | |
Thawkar et al. | Alzheimer’s disease preliminary screening in zebrafish integrating behavioral models and molecular markers | |
Bandaru et al. | Protective activity of ferulic acid on rotenone-induced Neurodegeneration in Zebra-fish model | |
Jega et al. | Manifestation of Functional Defects of Nervous System in Upf3 Mutants Drosophila melanogaster at Larval and Adult Stages | |
RU2781331C1 (ru) | Животная модель цинк-зависимого амилоидогенеза при болезни Альцгеймера | |
Ghidersa et al. | Behavioural and Metabolical Changes Associated with the Pathophysiology of Alzheimer’s Disease in Zebrafish | |
DE10217066A1 (de) | Neue Verwendung von neuronalem Calcium-Sensor-1 (NCS-1) bei der Therapie von ZNS-Erkrankungen und bei der Entwicklung von therapeutischen Mitteln | |
Cowen | Sleep, Sensory Sensitivity, and Socialization: Circuit Level Roles for Autism-Associated Genes in C. elegans Behavior |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
OL01 | Intention to license declared | ||
OL01 | Intention to license declared | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20181207 Assignee: Shandong Zeyu Biology Co.,Ltd. Assignor: BIOLOGY INSTITUTE OF SHANDONG ACADEMY OF SCIENCES Contract record no.: X2024980013482 Denomination of invention: A method for constructing an Alzheimer's disease model for drug screening Granted publication date: 20201030 License type: Open License Record date: 20240906 Application publication date: 20181207 Assignee: Shandong fengyinshengda Pharmaceutical Co.,Ltd. Assignor: BIOLOGY INSTITUTE OF SHANDONG ACADEMY OF SCIENCES Contract record no.: X2024980013406 Denomination of invention: A method for constructing an Alzheimer's disease model for drug screening Granted publication date: 20201030 License type: Open License Record date: 20240906 |